Bodes well for if and when Ryoncil is approved for adult aGVHD - it could gain approval from the FDA as a second line therapy and start making real inroads on Rux.
Haven’t got time but one could google Incyte for its financials to gauge size of market. Market share gains would of course have to be subject to some intelligent guessing. Some conservatism is warranted as one is talking about breaking into an established market as well as player.
Cell Therapy News/Articles, page-17617
-
- There are more pages in this discussion • 823 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
0.055(3.77%) |
Mkt cap ! $1.729B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.54 | $1.45 | $6.072M | 4.049M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5951 | $1.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 133644 | 5 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |